MedTrace Logo

A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)

NCT07613424 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2026-05-29

No results posted yet for this study

Summary

Multicenter prospective assessment of MET concordance and tumor gene profiling in treatment-naïve NSCLC

Conditions

Interventions

DIAGNOSTIC_TEST

NGS testing

NGS testing first for all participants and then cohort assignment for each participant can be derived based on NGS results.

DIAGNOSTIC_TEST

MET IHC testing

the participants of cohort 1 need to do MET IHC testing.

DIAGNOSTIC_TEST

PD-L1 and Her2 testing

the participants of cohort 1 need to do PD-L1 and Her2 testing.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07613424 on ClinicalTrials.gov